Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Basic science

1193 - Predictive value of the improvement in tumor microenvironment for progression in breast cancer patients treated with neoadjuvant chemotherapy (543O)


17 Nov 2017


Basic science


Translational Research;  Breast Cancer


Wataru Goto


Annals of Oncology (2017) 28 (suppl_10): x170-x172. 10.1093/annonc/mdx678


W. Goto1, S. Kashiwagi1, Y. Asano1, K. Takada1, K. Takahashi2, S. Noda1, T. Takashima1, N. Onoda1, S. Tomita2, K. Hirakawa1, M. Ohira3

Author affiliations

  • 1 Surgical Oncology, Osaka City University Medical School, 545-8585 - Osaka/JP
  • 2 Pharmacology, Osaka City University Medical School, 545-8585 - Osaka/JP
  • 3 Surgical Oncology, Osaka City University Graduate School of Medicine, 545-8585 - Osaka/JP


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 1193


Tumor-infiltrating lymphocytes (TILs) can be used to monitor the immune response, and are important in predicting treatment responses and outcomes for various types of cancer. In this study, we evaluated the prognostic significance of CD8+ TILs and FOXP3+ TILs before and after neoadjuvant chemotherapy (NAC).


Except for patients who achieved pathological complete response, 136 breast cancer patients treated with NAC were examined. CD8+ TILs and FOXP3+ TILs in biopsy specimens and residual tumors were evaluated by immunohistochemistry. CD8+ TILs and FOXP3+ TILs status was assessed, and the rates of their changes before and after NAC were calculated.


All patients with high rates of changes in the CD8+ TILs or low rates of changes in the FOXP3+ TILs or high rates of changes in the CD8/FOXP3 ratio (CFR) had significantly better recurrence-free survival (RFS) (P = 0.006, P = 0.044, P 


Improvement in immune microenvironment following NAC has a relationship with good outcome. In particular, rates of changes in the CFR may be a useful biomarker to predict prognosis of patients treated with NAC in all breast cancer subtypes.

Clinical trial identification

Legal entity responsible for the study

Shinichiro Kashiwagi




All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.